Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
By Bryan T. J. Hennessy, A. González-Angulo, K. Stemke‐Hale, M. Gilcrease, S. Krishnamurthy, Ju-Seog Lee, Jane Fridlyand, A. Sahin, R. Agarwal, C. Joy and 17 more. Cancer Research, 2009
863 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/ee4af9832626444055f7829071c95d2fbd2dd197
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features (2009, methodology): “However, a recent paper described similarities in gene expression patterns between metaplastic cancers and the ‘‘claudin low’’ subtype; metaplastic cancers are known to be more resistant to conventional chemotherapy (18).”
- Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes (2010, methodology): “(23) with the addition of 12 metaplastic tumors.”
- Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression (2010, background): “Markers of EMT are preferentially displayed in the basal subtype as well as in a newly recognized claudin-low subtype, linking EMT with the molecular subtype of a tumor [74, 75 ].”
- Triple-negative breast cancer: disease entity or title of convenience? (2010, background): “This subgroup is also notable for expression of cell–cell junction proteins and for the possession of stem-cell signatures and EMT characteristics with upregulation of mesenchymal markers”
- Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (2012, background): “It is a relatively rare subset of tumors (12–14%) clinically corresponding to high grade infiltrating ductal carcinomas, that can present metaplastic or medullary differentiation.(45,46)”
- Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review (2021, background): “Besides, these tumors show high expression of epithelial-mesenchymal transition (EMT) genes and stem cell-like gene expression patterns [169,170].”
- Deconstructing the molecular portraits of breast cancer (2010, background): “…signature (Taube et al., 2010), and show features of tumor initiating cells (TICs, also known as Cancer Stem Cells [CSCs]) (Creighton et al., 2009; Hennessy et al., 2009), the study of which is leading to the formulation of new hypothesis regarding the ‘cell of origin’ of the different subtypes…”
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists (2011, methodology): “78 using other molecular classification systems) or claudin-lo”
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. (2011, background): “A recent study found that 47% of metaplastic breast cancers sequenced have PIK3CA mutations and have higher phosho-AKT expression (54).”
- Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. (2009, background): “Metaplastic breast cancers, a subtype of the basal-like group that is largely chemoresistant, were reported recently to have a distinct molecular profile that most closely resembles that of the claudin-low subgroup and is enriched for epithelial– mesenchymal transition (EMT) signature genes (Henness”
- The ins and outs of the epithelial to mesenchymal transition in health and disease. (2011, background): “Metasplastic and claudin-low breast carcinomas are also examples of tumors prone to undergo the EMT (Hennessy et al. 2009, Taube et al. 2010).”